Compare CI & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CI | BSX |
|---|---|---|
| Founded | 1792 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.9B | 68.0B |
| IPO Year | 2018 | 2010 |
| Metric | CI | BSX |
|---|---|---|
| Price | $273.16 | $43.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 22 |
| Target Price | ★ $349.00 | $93.18 |
| AVG Volume (30 Days) | 1.3M | ★ 18.2M |
| Earning Date | 04-30-2026 | 04-22-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | ★ 83.00 | 55.20 |
| EPS | ★ 12.55 | 1.51 |
| Revenue | ★ $274,900,000,000.00 | $9,076,000,000.00 |
| Revenue This Year | $5.91 | $11.85 |
| Revenue Next Year | $5.92 | $10.16 |
| P/E Ratio | ★ $21.66 | $29.21 |
| Revenue Growth | 11.24 | ★ 12.49 |
| 52 Week Low | $239.51 | $42.20 |
| 52 Week High | $315.47 | $105.65 |
| Indicator | CI | BSX |
|---|---|---|
| Relative Strength Index (RSI) | 45.87 | 39.87 |
| Support Level | $271.75 | $42.49 |
| Resistance Level | $286.84 | $46.37 |
| Average True Range (ATR) | 5.91 | 1.12 |
| MACD | -0.78 | 0.03 |
| Stochastic Oscillator | 35.68 | 22.02 |
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is with the Department of Defense, and it recently won a multiyear deal with top-tier insurer Centene. In health insurance and other benefits, Cigna primarily serves employers through self-funding arrangements, and the company operates mostly in the US with 16 million US and 2 million international medical members covered as of December 2025.
Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.